Clinical Observation Of Modified Huangqi Chifeng Decoction In Treating Post-stroke Depression

Objective: To observe the clinical efficacy of Jiawei Huangqi Chifeng Decoction in treating mild to moderate depression after stroke of qi deficiency,blood stasis,stagnation of liver qi.Methods: From September 2018 to October 2019,inpatients and outpatients in the Department of Encephalology of Hebei Provincial Hospital of Traditional Chinese Medicine were selected to meet the inclusion criteria for post-stroke depression(PSD).A total,including 63 patients.Randomized grouping,divided into treatment group of 32 cases and control group of 31 cases,and based on stroke and basic disease treatment,the control group was given flupentixol and melitrazine tablets(trade name: Daixinxin)orally.1tablet,1 / day,morning service;the treatment group was given modified Huangqi Chifeng decoction granules based on the control group,and the traditional Chinese medicine was added or subtracted with the certificate,one dose per day,divided into two boxes in the morning and evening.The course of treatment was 8 weeks.The scores of the relevant scales were scored before and after treatment,and the adverse reactions during the medication were recorded.Data analysis was performed using SPSS 26.0 statistical software.Result:Sixty-three cases were included in the course of this trial,and a total of three cases fell off during the process.One patient in the treatment group fell off due to loss of contact with the phone,and one patient dropped out because of his own.One patient in the control group fell off because he did not visit the clinic as scheduled.The number of cases was 60 cases,30 cases in the treatment group and 30 cases in the control group.1.Clinical effectiveness: The clinical effectiveness of TCM in the treatment group and control group was 86.7% and 66.7%,respectively.The clinical efficacy rates of the 24 items of the Hamilton Depression Scale(HDRS-24)were 80.0% and 60.0%,respectively.The clinical efficacy of the treatment group was significantly better than that of the control group.2.Observation of efficacy indicators:(1)HDRS score: There was no significant difference between the two groups of HDRS scores before treatment(P> 0.05).After 4 weeks and 8weeks of treatment,the HDRS score of the treatment group was lower than that of the control group(P <0.05).(2)National Institutes of Health Stroke Scale(NIHSS)score: There was no significant difference between the groups before treatment(P> 0.05).After 4weeks and 8weeks of treatment,the reduction in the NIHSS score of the treatment group was better than that of the control group(P <0.05).(3)TCM depression scale score: there was no significant difference between the two groups of TCM depression scale scores before treatment(P> 0.05).After 4weeks and 8weeks of treatment,the TCM depression scale score of the treatment group was lower than that of the control group(P <0.05).3.Safety: No serious adverse reactions occurred during the treatment of the two groups of patients.Conclusion:1.Modified Huangqi Chifeng Decoction for the treatment of Qi deficiency,blood stasis and stagnation of liver qi type PSD has exact clinical efficacy,can improve the clinical symptoms of patients with mild to moderate depression after stroke,and has fewer adverse reactions.2.Modified Huangqi Chifeng Decoction was significantly better than the control group in reducing the scores of the HDRS Depression Scale,the NIHSS Scale,and the TCM Depression Scale,which is worthy making further study.